Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma | Zendy

ChengWen Lin | Zendy; Bryan W. Sherman | Zendy; Lori Moore | Zendy; Carmen Laethem | Zendy; DaWen Lu | Zendy; Padmanabhan P. Pattabiraman | Zendy; Ponugoti Vasantha Rao | Zendy; Mitchell A. deLong | Zendy; Casey Kopczynski | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma

Author(s) -

ChengWen Lin,

Bryan W. Sherman,

Lori Moore,

Carmen Laethem,

DaWen Lu,

Padmanabhan P. Pattabiraman,

Ponugoti Vasantha Rao,

Mitchell A. deLong,

Casey Kopczynski

Publication year - 2017

Publication title -

journal of ocular pharmacology and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.727

H-Index - 61

eISSN - 1557-7732

pISSN - 1080-7683

DOI - 10.1089/jop.2017.0023

Subject(s) - rho kinase inhibitor , rho associated protein kinase , trabecular meshwork , pharmacology , in vivo , intraocular pressure , tolerability , glaucoma , rock2 , pharmacokinetics , medicine , ocular hypertension , kinase , chemistry , adverse effect , ophthalmology , biology , biochemistry , microbiology and biotechnology

Rho-associated protein kinase (ROCK) inhibitors lower intraocular pressure (IOP) by increasing aqueous outflow through the trabecular meshwork (TM). The preclinical characterization of netarsudil, a new ROCK/norepinephrine transporter (NET) inhibitor currently in clinical development, is presented herein.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research